Literature DB >> 7947026

The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients.

J F Crocker1, K W Renton, T L LeVatte, D H McLellan.   

Abstract

The elimination of cyclosporin A was assessed in eight pediatric renal transplant patients who received calcium channel blockers concomitantly with their immunosuppressive therapy. In three children, verapamil decreased the rate of elimination of cyclosporin A. In five children who received nifedipine, cyclosporin A elimination was also impaired, which contrasts with the reports in adult patients indicating that this calcium channel blocker has no effect on cyclosporin A elimination. When both calcium channel blockers were used on separate occasions in the same patient, nifedipine was less potent than verapamil in depressing cyclosporin A elimination. Although the number of subjects studied is small, these results likely indicate that nifedipine, as well as other calcium channel blocking drugs, must be used with caution in pediatric renal transplant patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947026     DOI: 10.1007/bf00856514

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  36 in total

Review 1.  An appraisal of drug interactions with Sandimmun.

Authors:  I T Cockburn; P Krupp
Journal:  Transplant Proc       Date:  1989-10       Impact factor: 1.066

2.  Cyclosporin A and hypertension in pediatric renal transplant recipients.

Authors:  M R Ogborn; J F Crocker; P Belitsky; A S MacDonald; H Bitter-Suermann; S C Digout
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

Review 3.  Cyclosporin- and nifedipine-induced gingival enlargement: an overview.

Authors:  P M De Camargo
Journal:  J West Soc Periodontol Periodontal Abstr       Date:  1989

4.  Cyclosporine-associated posttransplant hypertension incidence and effect on renal transplant function.

Authors:  T Schorn; U Frei; H Brackmann; M Lorenz; P Vogt; B Wiese; R Pichlmayr; K M Koch
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

5.  Hypertension and convulsions in children receiving cyclosporin A.

Authors:  D V Joss; A J Barrett; J R Kendra; C F Lucas; S Desai
Journal:  Lancet       Date:  1982-04-17       Impact factor: 79.321

6.  Inhibition of cyclosporine metabolism by other drugs in vitro.

Authors:  S Henricsson; A Lindholm
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

7.  Influence of diltiazem on cyclosporin clearance.

Authors:  J M Griño; I Sabate; A M Castelao; J Alsina
Journal:  Lancet       Date:  1986-06-14       Impact factor: 79.321

8.  Prevention of delayed graft function in cadaver kidney transplants by diltiazem.

Authors:  K Wagner; H H Neumayer
Journal:  Lancet       Date:  1985-12-14       Impact factor: 79.321

9.  The effect of verapamil on cellular uptake, organ distribution, and pharmacology of cyclosporine.

Authors:  M A McMillen; W K Baumgarten; H C Schaefer; E Mitchnick; M Fuortes; M J Holman; R J Tesi
Journal:  Transplantation       Date:  1987-09       Impact factor: 4.939

10.  Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA.

Authors:  M R Lucey; J C Kolars; R M Merion; D A Campbell; M Aldrich; P B Watkins
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

View more
  5 in total

1.  Prediction of systemic exposure to cyclosporine in Japanese pediatric patients.

Authors:  Toshiyuki Sakaeda; Kazumoto Iijima; Kandai Nozu; Tsutomu Nakamura; Yuka Moriya; Mika Nishikawa; Atsushi Wada; Noboru Okamura; Masafumi Matsuo; Katsuhiko Okumura
Journal:  J Hum Genet       Date:  2006-09-14       Impact factor: 3.172

2.  Age effect on whole blood cyclosporine concentrations following oral administration in children with nephrotic syndrome.

Authors:  Katsumi Ushijima; Osamu Uemura; Takuji Yamada
Journal:  Eur J Pediatr       Date:  2011-11-26       Impact factor: 3.183

3.  Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients.

Authors:  K R Yeo; W W Yeo; E J Wallis; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 4.  The management of hypertensive emergencies in children after stem cell transplantation.

Authors:  D G Horn; M N Trame; G Hempel
Journal:  Int J Clin Pharm       Date:  2011-03-12

5.  A comparison of the pharmacokinetics of tacrolimus and microemulsified cyclosporin in paediatric renal transplant recipients.

Authors:  Kenneth W Renton; John F S Crocker; Heather McLellan; Philip D Acott
Journal:  Eur J Clin Pharmacol       Date:  2004-07-01       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.